Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 5/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24580398 | 1.00 | PRCP (0.44) | PRCPTLR2TLR1CMA1ACE | |
| SCHEMBL29696666 | 0.93 | PRCP (0.43) | PRCPTLR2TLR1CMA1ITGB3 | |
| SCHEMBL30640764 | 0.91 | PRCP (0.51) | PRCPTLR2TLR1CMA1ACE | |
| SCHEMBL29696668 | 0.91 | PRCP (0.51) | PRCPTLR2TLR1CMA1ACE | |
| SCHEMBL15960070 | 0.91 | PRCP (0.51) | PRCPTLR2TLR1CMA1ACE | |
| SCHEMBL24580399 | 0.87 | PRCP (0.42) | PRCPCMA1ACEACE2REN | |
| SCHEMBL24580344 | 0.85 | PRCP (0.51) | PRCPTLR2TLR1CMA1ACE | |
| SCHEMBL24580397 | 0.84 | PRCP (0.37) | PRCPTLR2TLR1CMA1ITGB3 | |
| SCHEMBL24579348 | 0.84 | ACE (0.52) | CMA1ACEACE2 | |
| SCHEMBL30640786 | 0.84 | ACE (0.52) | CMA1ACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | PRCP 127/4885TLR2 3384/4885TLR1 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.